MedTrace Logo

Improve PAD PERformance With METformin

NCT03054519 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2026-04-15

No results posted yet for this study

Summary

The PERMET trial will determine whether metformin daily for six months improves six-minute walk performance in individuals with peripheral artery disease compared to placebo.

Conditions

Interventions

DRUG

Metformin

Participants will be prescribed up to 2,000 mgs daily of metformin

DRUG

Placebo

Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.

Sponsors & Collaborators

Principal Investigators

  • Mary McDermott, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-23
Primary Completion
2025-08-20
Completion
2025-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03054519 on ClinicalTrials.gov